Insider Selling: OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Sells 5,310 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the sale, the general counsel now owns 110,767 shares in the company, valued at $2,753,667.62. The trade was a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

OrthoPediatrics Trading Up 1.8 %

Shares of KIDS traded up $0.46 during trading hours on Tuesday, hitting $25.42. 138,044 shares of the stock traded hands, compared to its average volume of 162,840. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The firm has a market capitalization of $617.38 million, a PE ratio of -20.67 and a beta of 1.22. The business has a fifty day moving average of $24.74 and a 200-day moving average of $25.62.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. Analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Hedge Funds Weigh In On OrthoPediatrics

Several large investors have recently made changes to their positions in KIDS. Quarry LP acquired a new position in OrthoPediatrics in the third quarter valued at about $25,000. R Squared Ltd acquired a new position in OrthoPediatrics in the fourth quarter valued at about $48,000. KLP Kapitalforvaltning AS acquired a new position in OrthoPediatrics in the fourth quarter valued at about $79,000. BNP Paribas Financial Markets lifted its stake in OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after buying an additional 1,929 shares during the period. Finally, Quantbot Technologies LP lifted its stake in OrthoPediatrics by 42.2% in the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after buying an additional 1,712 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Stifel Nicolaus decreased their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Truist Financial decreased their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.